Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 11/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7250524 | 0.91 | KCNH2 (0.44) | ALDH1A1CCR5GAASMN1; SMN2KCNH2 | |
| SCHEMBL7257279 | 0.88 | KCNA5 (0.44) | ALDH1A1CCR5JAK2JAK3MCHR1 | |
| SCHEMBL7249989 | 0.88 | CCR5 (0.38) | ALDH1A1CCR5JAK2JAK3MCHR1 | |
| SCHEMBL7243596 | 0.87 | KCNA5 (0.45) | ALDH1A1CCR5MCHR1KCNH2 | |
| SCHEMBL7249993 | 0.84 | CCR5 (0.38) | ALDH1A1CCR5MCHR1GAASMN1; SMN2 | |
| SCHEMBL6095709 | 0.83 | GRIN2B (0.44) | ALDH1A1TRPV4GAASMN1; SMN2 | |
| SCHEMBL7248380 | 0.82 | KCNH2 (0.39) | ALDH1A1CCR5KCNH2 | |
| SCHEMBL7244454 | 0.81 | KCNH2 (0.38) | ALDH1A1KCNH2 | |
| SCHEMBL7248521 | 0.81 | MCHR1 (0.41) | CCR5MCHR1KCNH2 | |
| SCHEMBL7243515 | 0.80 | MGLL (0.44) | ALDH1A1TRPV4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559162-B2 | Electrophysiological activity | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | KCNH1, KCNH2, KCNH3 | ALDH1A1 315/4885CCR5 3571/4885JAK2 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.